Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.450
-0.140 (-3.90%)
At close: Jul 3, 2025, 1:00 PM
3.390
-0.060 (-1.74%)
After-hours: Jul 3, 2025, 4:59 PM EDT

Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $124.15 million. The enterprise value is $92.37 million.

Market Cap 124.15M
Enterprise Value 92.37M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025, after market close.

Earnings Date Aug 5, 2025
Ex-Dividend Date n/a

Share Statistics

Immuneering has 35.99 million shares outstanding. The number of shares has increased by 8.14% in one year.

Current Share Class 35.99M
Shares Outstanding 35.99M
Shares Change (YoY) +8.14%
Shares Change (QoQ) +14.43%
Owned by Insiders (%) 24.35%
Owned by Institutions (%) 12.49%
Float 27.22M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 2.97
P/TBV Ratio 3.57
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.48, with a Debt / Equity ratio of 0.10.

Current Ratio 7.48
Quick Ratio 7.02
Debt / Equity 0.10
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -102.48% and return on invested capital (ROIC) is -62.22%.

Return on Equity (ROE) -102.48%
Return on Assets (ROA) -57.90%
Return on Invested Capital (ROIC) -62.22%
Return on Capital Employed (ROCE) -140.94%
Revenue Per Employee n/a
Profits Per Employee -$935,984
Employee Count 66
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +216.51% in the last 52 weeks. The beta is 0.37, so Immuneering's price volatility has been lower than the market average.

Beta (5Y) 0.37
52-Week Price Change +216.51%
50-Day Moving Average 1.93
200-Day Moving Average 1.94
Relative Strength Index (RSI) 67.77
Average Volume (20 Days) 2,919,594

Short Selling Information

The latest short interest is 893,835, so 2.48% of the outstanding shares have been sold short.

Short Interest 893,835
Short Previous Month 924,552
Short % of Shares Out 2.48%
Short % of Float 3.28%
Short Ratio (days to cover) 3.13

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -64.23M
Pretax Income -56.07M
Net Income -61.77M
EBITDA -63.85M
EBIT -64.23M
Earnings Per Share (EPS) -$1.96
Full Income Statement

Balance Sheet

The company has $35.87 million in cash and $4.08 million in debt, giving a net cash position of $31.78 million or $0.88 per share.

Cash & Cash Equivalents 35.87M
Total Debt 4.08M
Net Cash 31.78M
Net Cash Per Share $0.88
Equity (Book Value) 41.84M
Book Value Per Share 1.16
Working Capital 33.10M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$53.59 million and capital expenditures -$56,342, giving a free cash flow of -$53.65 million.

Operating Cash Flow -53.59M
Capital Expenditures -56,342
Free Cash Flow -53.65M
FCF Per Share -$1.49
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -8.14%
Shareholder Yield -8.14%
Earnings Yield -49.76%
FCF Yield -43.21%

Analyst Forecast

The average price target for Immuneering is $13.25, which is 284.06% higher than the current price. The consensus rating is "Strong Buy".

Price Target $13.25
Price Target Difference 284.06%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) -68.00%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1